Advertisement
BAX vs MDT
Which Stock Would AI Choose? Baxter International (BAX) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- BAX is a turnaround story gaining momentum after raising its 2026 guidance, though margin pressure and a product-hold overhang persist.
- MDT offers scale, a 3.2% dividend yield, and 49 consecutive years of payout increases, but the stock has lagged the broader market in recent months.
- Baxter trades as a smaller, higher-risk/higher-reward recovery play, while Medtronic represents a diversified, cash-generative large-cap.
- Medtronic's cardiac ablation and robotics momentum contrasts with Baxter's dependence on a still-unresolved infusion pump hold.
- Relative performance has diverged sharply: Baxter's shares rallied on its latest earnings, while Medtronic's reaction was comparatively muted.
Introduction
Medical technology is a sector where durability and execution matter as much as innovation. This stock comparison examines two established healthcare names at very different stages: BAX, the Deerfield, Illinois-based maker of IV (intravenous) solutions and infusion systems working through a turnaround, and MDT, the Irish-headquartered medical device giant delivering its strongest growth in a decade. Investors weighing a recovery thesis against a steady, dividend-paying compounder will find the contrast instructive. This article reviews each company's recent performance, market positioning, and the observable factors that could shape relative performance in the months ahead.
BAX Overview and Recent Performance
Baxter International (BAX) provides essential hospital products, including IV solutions, infusion pumps, surgical sealants, and patient monitoring technologies. The company recently simplified its portfolio by divesting its Kidney Care business, sharpening its focus on core medical products. In its latest quarter, Baxter reported revenue of roughly $2.96 billion, up about 5% organically, and meaningfully beat analyst expectations for adjusted earnings per share (EPS, a measure of profitability per share). Management responded by raising its full-year 2026 sales growth outlook to 3% to 4% and its adjusted EPS guidance to a range of $1.95 to $2.15.
The stock surged by roughly 15% on the news, a notable shift in sentiment after a prolonged period of underperformance. However, the picture is not uniformly positive. Adjusted gross margin fell 210 basis points to 38.6%, and the ongoing shipment and installation hold on the Novum IQ large-volume infusion pump continues to weigh on the Infusion Systems franchise. These factors, alongside pricing pressure from hospital group purchasing organizations and China procurement, mean the turnaround remains incomplete even as demand trends improve.
MDT Overview and Recent Performance
Medtronic (MDT) is one of the world's largest medical device companies, operating across cardiovascular, neuroscience, medical-surgical, and diabetes-related portfolios. For its fiscal year 2026, Medtronic delivered revenue of about $36.4 billion, up 8.4% as reported, which management described as its highest annual growth in a decade. Cardiac Ablation Solutions has been a standout, with pulsed field ablation (PFA, a catheter-based treatment for irregular heart rhythms) growing sharply and driving market-share gains.
Despite strong fundamentals, Medtronic's stock has struggled, down year-to-date and over the past five years, and its latest fiscal first-quarter report drew a relatively tepid market reaction. Investors have focused on margin impacts from tariffs and the recent spinoff of its diabetes business, as well as heavy investment in the Hugo robotic-assisted surgery platform. The company's forward price-to-earnings (P/E) ratio of roughly 15 sits at a discount to peers, and its dividend yield has risen to about 3.2%, supported by improving free cash flow.
Trending AI Robots
For traders seeking a data-driven edge across names like these, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and watchlist of securities. Because not every bot suits every market environment, only the most relevant and best-performing ones are highlighted in the Trending AI Robots section, helping users identify approaches aligned with current conditions. Exploring the Trending AI Robots page can help traders discover automated strategies matched to their own objectives and risk tolerance.
Head-to-Head Comparison
The clearest contrast between these two stocks is scale and stage of maturity. MDT is a diversified large-cap with broad geographic reach, multiple growth engines, and a reliable dividend; BAX is a mid-cap focused on a narrower set of hospital essentials, with a smaller market capitalization and a recently trimmed dividend that reflects balance-sheet repair priorities.
Growth drivers also differ. Medtronic's momentum is anchored in innovation-led categories such as PFA, renal denervation, and surgical robotics, whereas Baxter's near-term story is driven by operational execution, cost discipline, and volume recovery in IV solutions and drug compounding. On the risk side, Baxter faces a concrete regulatory and commercial overhang in the Novum IQ hold and persistent margin compression, while Medtronic contends with tariff costs, post-spinoff integration expenses, and competitive pricing pressure in neuroscience.
Sentiment has recently favored Baxter, whose earnings beat triggered a sharp rally, while Medtronic's equally solid results received a more muted reception—suggesting investors are already pricing in Medtronic's steadiness but still rewarding Baxter's turnaround progress. For income-oriented investors, MDT's 3.2% yield stands in stark contrast to Baxter's nominal payout, making the two stocks appealing to different profiles.
Tickeron AI Verdict
Based on observable trend consistency, catalysts, and relative positioning, Tickeron's AI would likely lean toward MDT for its stability and breadth, while recognizing that BAX currently shows stronger short-term momentum. Medtronic's diversified growth, improving free cash flow, and dependable dividend provide a more consistent and defensible trend profile. Baxter's sharper upside, driven by its guidance raise and recovery narrative, is accompanied by higher execution uncertainty around margins and the infusion pump hold. A probability-weighted assessment would therefore tend to favor Medtronic for risk-adjusted consistency, while acknowledging Baxter's appeal as a higher-beta, catalyst-driven opportunity for traders with a shorter time horizon.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Hold and MDT is a Hold.
BAX | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 68 | |
PRICE GROWTH RATING 1..100 | 46 | 55 | |
P/E GROWTH RATING 1..100 | 26 | 57 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for BAX (98). This means that MDT’s stock grew significantly faster than BAX’s over the last 12 months.
MDT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
MDT's SMR Rating (68) in the Medical Specialties industry is in the same range as BAX (94). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
BAX's Price Growth Rating (46) in the Medical Specialties industry is in the same range as MDT (55). This means that BAX’s stock grew similarly to MDT’s over the last 12 months.
BAX's P/E Growth Rating (26) in the Medical Specialties industry is in the same range as MDT (57). This means that BAX’s stock grew similarly to MDT’s over the last 12 months.
| BAX | MDT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 57% | N/A |
| Stochastic ODDS (%) | 3 days ago 59% | 3 days ago 48% |
| Momentum ODDS (%) | 3 days ago 53% | 3 days ago 54% |
| MACD ODDS (%) | 3 days ago 41% | 7 days ago 45% |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 52% |
| Advances ODDS (%) | 13 days ago 57% | 7 days ago 54% |
| Declines ODDS (%) | 3 days ago 67% | 5 days ago 55% |
| BollingerBands ODDS (%) | 3 days ago 66% | 3 days ago 58% |
| Aroon ODDS (%) | 3 days ago 56% | 3 days ago 43% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 1 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- BAX’s FA Score: 1 green, 4 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 6 TA indicator(s) are bullish while MDT’s TA Score has 4 bullish TA indicator(s).
- BAX’s TA Score: 6 bullish, 4 bearish.
- MDT’s TA Score: 4 bullish, 6 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а +0.51% price change this week, while MDT (@Medical/Nursing Services) price change was -2.55% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.16%. For the same industry, the average monthly price growth was -5.16%, and the average quarterly price growth was +14.10%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.13%. For the same industry, the average monthly price growth was -5.92%, and the average quarterly price growth was -2.70%.
Reported Earning Dates
BAX is expected to report earnings on Oct 29, 2026.
MDT is expected to report earnings on Nov 24, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.16% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-2.13% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with LUNG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | -0.63% | ||
| LUNG - BAX | 53% Loosely correlated | -4.19% | ||
| ICUI - BAX | 52% Loosely correlated | +1.40% | ||
| STE - BAX | 51% Loosely correlated | -0.38% | ||
| SYK - BAX | 51% Loosely correlated | +0.90% | ||
| SOLV - BAX | 48% Loosely correlated | +0.09% | ||
More | ||||
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.